大理大学学报 ›› 2022, Vol. 7 ›› Issue (10): 22-27.

• 药学 • 上一篇    下一篇

某医院心力衰竭住院患者沙库巴曲缬沙坦的用药分析

李秋镜,郭 羽,赵燕菊,沈 磊*   

  1. 1.大理大学药学院,云南大理 6710002.大理大学第一附属医院药剂科,云南大理 671000

  • 收稿日期:2022-05-09 修回日期:2022-09-02 出版日期:2022-10-15 发布日期:2022-11-15
  • 通讯作者: 沈磊,副教授,博士,E-mail:shenlei@dali.edu.cn。
  • 作者简介:李秋镜,硕士研究生,主要从事临床药学研究。
  • 基金资助:

    云南省基础研究计划项目(202101AT070030

Analysis of the Application of Sacubitril-Valsartan in Inpatients with Heart Failure in a Hospital

Li QiujingGuo YuZhao YanjuShen Lei*   

  1. 1. College of PharmacyDali UniversityDaliYunnan 671000China2. Department of PharmacyThe First Affiliated Hospital of Dali UniversityDaliYunnan 671000China

  • Received:2022-05-09 Revised:2022-09-02 Online:2022-10-15 Published:2022-11-15

摘要:

[摘要] 目的:分析大理大学第一附属医院心力衰竭住院患者沙库巴曲缬沙坦的用药情况,为该药的临床合理应用提供参考。方法:利用医院信息系统收集2020612月该院使用沙库巴曲缬沙坦的住院患者的基本情况,回顾性分析药物应用情况。结果:共纳入213例有适应证患者,其中存在相对用药禁忌证的有42例,起始剂量或用药频次不合理的有49例,靶剂量不达标的有173例;93例使用ACEIARB后转换为沙库巴曲缬沙坦,转换不合理的有28例;用药前后相比,无相对禁忌证患者心功能得到明显改善,而有相对禁忌证患者肾功能有较明显改善;49例发生药品不良反应。结论:该院心力衰竭患者使用沙库巴曲缬沙坦存在一些不合理情况,表现为存在相对用药禁忌证、初始给药剂量偏低、靶剂量达标率低、药物转换时机不适宜等,建议医疗机构规范该药的临床应用。

关键词:

"> font-size:10.5pt, ">沙库巴曲缬沙坦, 心力衰竭, 合理用药, 有效性, 安全性

Abstract:

AbstractObjectiveTo analyze the application of sacubitril-valsartan in inpatients with heart failure in the First Affiliated Hospital of Dali Universityso as to provide a basis for clinical rational use of the drug. MethodsThe hospital information system was used to collect the basic information of inpatients who used sacubitril-valsartan from June to December 2020and the application of the drug was retrospectively analyzed. ResultsA total of 213 patients with indications were enrolledand 42 cases had relative drug contraindications. The initial dose or frequency were unreasonable in 49 casesand the target dose was not up to standard in 173 cases. There were 93 cases treated with ACEI or ARB converted to the application of sacubitril-valsartanand 28 cases were not properly converted. Compared to the situation before treatmentthe cardiac function of patients without relative contraindications improved significantlywhile the renal function of patients with relative contraindications improved obviously. 49 cases had adverse drug reaction. ConclusionThere are some unreasonable situations in the use of sacubitril-valsartan in patients with heart failure in this hospitalsuch as relative medication contraindicationslow initial doselow rate of target dose reaches to standardand inappropriate drug timing of drug conversion. It is suggested that medical institutions should standardize the clinical application of the drug.

Key words:

"> font-size:10.5pt, ">sacubitril-valsartan, heart failure, rational drug use, effectiveness, safety

中图分类号: